To include your compound in the COVID-19 Resource Center, submit it here.

Revlimid lenalidomide: Phase III started

Celgene and Groupe d'Etude des Lymphomes de l'Adulte (GELA) began the open-label, international Phase III RELEVANCE trial to compare

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE